China Resources Sanjiu: Announcement on the purchase of bank financial products
Stock code: 000999 Stock abbreviation: China Resources Sanjiu Announcement number: 2026-034
China Resources Sanjiu Pharmaceutical Co., Ltd.
Announcement on purchasing bank financial products
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Overview of investment banking financial products
The authorization quota for China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "China Resources Sanjiu") to purchase bank financial products is about to expire. In order to make reasonable use of idle funds, and after fully considering the company's future working capital and comprehensive assessment of risks and returns, the company and its subsidiaries plan to use a total of no more than RMB 10 billion of their own funds (of which the company's holding subsidiary Kunyao Group Co., Ltd.'s quota will not exceed RMB 2 billion, and the quota of Tasly Pharmaceutical Group Co., Ltd. will not exceed RMB 4 billion), investment banks and its affiliated bank wealth management subsidiaries wealth management products (excluding Guangdong China Resources Bank wealth management products). The funds can be used on a rolling basis, and the term of a single product shall not exceed six months (including six months). The investment period shall be from the moment the shareholders meeting approves this proposal to September 10, 2027.
Investment purpose: Make full use of some of the company's existing idle funds, improve the efficiency of fund use, and increase the income level of funds.
Investment methods: fixed-income non-principal-guaranteed floating-income financial products (risk rating below R2 (including R2)) and bank structured deposits of banks and their bank wealth management subsidiaries (excluding Guangdong China Resources Bank); the single term shall not exceed six months (including six months). Funds will not be directly invested in high-risk products such as stocks, bonds, funds, foreign exchange and their derivatives in the securities market.
Investment period: from the date of approval by the shareholders’ meeting to September 10, 2027.
Investment limit: no more than 10 billion yuan. Within the above limit, funds can be used on a rolling basis, and the transaction amount at any point in the period (including the amount related to reinvestment of the aforementioned investment income) does not exceed 10 billion yuan.
Source of funds: own funds.
2. Approval Procedure
This transaction has been reviewed and approved by the company's seventh meeting of the board of directors in 2026 held on August 21, 2026, and will be submitted to the company's shareholders' meeting for review. This transaction does not constitute a related transaction, and the review procedures for this transaction comply with relevant laws, regulations and other regulations.
Within the above quota and period, it is recommended that the company's shareholders meeting authorize the company's board of directors, and the board of directors authorize the management to select bank and its affiliated bank wealth management subsidiaries' wealth management products and bank structured deposits for investment within the approved scope based on market conditions, and go through relevant procedures with the relevant banks and their affiliated bank wealth management subsidiaries.
Kunyao Group Co., Ltd. and Tasly Pharmaceutical Group Co., Ltd. are authorized by their shareholders' meetings to authorize their boards of directors, and their boards of directors to authorize their company management to select bank and its affiliated wealth management subsidiaries' wealth management products and bank structured deposits for investment within the scope of approval within the scope of their quotas, and to go through relevant procedures with the relevant banks and their affiliated wealth management subsidiaries.
3. Risks and control measures
- Investment risks:
Although the financial management products the company intends to purchase are fixed-income non-principal-guaranteed floating-income financial products and bank structured deposits, the financial market is greatly affected by macroeconomic, fiscal and monetary policies. It cannot be ruled out that the investment will be affected by market fluctuations. The company will intervene in a timely and appropriate amount based on changes in the economic situation and financial markets, so the actual returns from short-term investments are unpredictable.
- In response to investment risks, the following measures are planned:
The company will carry out relevant financial management business in strict accordance with the requirements of the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant laws and regulations, normative documents and the "Articles of Association", and will strengthen the analysis and research of relevant financial management products, conscientiously implement the company's various internal control systems, and strictly control investment risks.
The company has formulated internal control systems such as the "Cash Financial Management Management System", which stipulates in detail the principles, scope, authority, internal review process, supervision of fund use, responsible departments and responsible persons for investment and financial management, in order to prevent financial risks and ensure the safety of funds. The company's financial management center has dedicated personnel to manage various financial products during their duration, strengthen regular tracking, and strictly control risks.
4. Impact on the company
The company adheres to the principles of "standardized operations, risk prevention, prudent investment, and value preservation and appreciation." On the premise of ensuring the company's daily operations and capital security, the company uses its own idle funds to moderately invest in medium- and low-risk financial products and bank structured deposits, which will not affect the normal development of the company's main business. By conducting moderate short-term financial management with medium and low risks, certain investment benefits can be obtained and more investment returns can be achieved for the company's shareholders.
The company will carry out corresponding accounting treatment in accordance with relevant regulations such as "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" and combined with the nature of the financial products purchased. The specific annual audit results shall prevail.
5. Documents for reference
- Resolution of the seventh meeting of the Board of Directors in 2026
Announcement is hereby made.
Board of Directors of China Resources Sanjiu Pharmaceutical Co., Ltd.
August 21, 2026